Navigation Links
BridgePoint Medical Completes First U.S. Clinical Case Using CrossBoss and Stingray Devices in CTO Angioplasty Procedure

MINNEAPOLIS, March 11 /PRNewswire/ -- BridgePoint Medical, Inc.(TM), a leading medical technology company focused on the treatment of coronary and peripheral vascular disease, has completed the first human clinical case in the United States using its CrossBoss(TM) CTO Catheter and Stingray(TM) CTO Re-Entry System. The CrossBoss CTO Catheter and Stingray CTO Re-Entry System are under clinical investigation to demonstrate safety and effectiveness in the treatment of completely blocked arteries known as Chronic Total Occlusions (CTO). BridgePoint Medical's clinical trial, Facilitated Antegrade Steering Technique for Chronic Total Occlusions (FAST-CTOs), was conditionally approved in January 2009 by the FDA.

The first clinical case was completed by Dr. William Lombardi, Interventional Cardiologist and Cardiac Catheterization Lab Director at North Cascade Cardiology in Bellingham, Washington. The patient was a 61 year old woman with a chronic total occlusion of her right coronary artery, chest pain (characterized as level three angina) and a positive stress test. The patient was referred to Dr. Lombardi for inclusion in BridgePoint Medical's FAST-CTOs clinical trial after a failed treatment attempt to cross the lesion by a referring physician.

Procedural completion took 35 minutes, resulting in the opening of the completely blocked vessel and return of normal blood flow to the patient's heart. "The BridgePoint Medical System allowed me to open this challenging total occlusion," stated Dr. Lombardi. "BridgePoint Medical's clinical trial is designed to demonstrate the CrossBoss CTO Catheter and the Stingray Re-Entry System are broadly effective in re-establishing blood flow across completely blocked arteries and these devices will hopefully provide improved options for patient care." The patient was released from the hospital the day after the procedure.

Annually 1.3 million worldwide patients suffer from chronic total occlusions of coronary arteries. Interventional cardiologists are currently unable to broadly treat patients with chronic total occlusions, which comprise approximately one third of all patients diagnosed with coronary artery disease. For these patients, a common alternative is open heart bypass surgery or palliative medical care.

"We are very excited about the start of our United States clinical trial," said Chad Kugler, Co-Founder, President and General Manager of BridgePoint Medical. "We believe that our crossing systems will be demonstrated to provide a viable non-surgical alternative to this challenging form of heart disease."

About BridgePoint Medical

BridgePoint Medical, Inc. is a privately held company established in 2006 to design, develop and commercialize new technologies and techniques to treat challenging coronary artery disease. Investors include New Enterprise Associates, Polaris Venture Partners, Foundation Medical Partners and Michael Berman.

SOURCE BridgePoint Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Amy Street, Certified Prosthetist and Orthotist, Joins BridgePoint Medical Partner, Charlotte Orthotic and Prosthetic Center (COPC)
2. ASM Announces Seminars on Materials and Processes for Medical Devices
3. iVolution Medical Systems Acquires Professional Healthcare Billing Services
4. Medical Insurance Coverage in Africa a Possible Key to Improved Healthcare Access, States Frost & Sullivan
5. Kennedy Group Applies Its Packaging Expertise to Reusable Labeling in Handling Biomedical Waste Disposal
6. Devicor Medical Products Actively Seeking First Acquisition
7. Danube(TM) Technologies Jim Schiel to Share Scrum Best Practices Learned From Siemens Medical Solutions Project
8. Leading German Healthcare Group Selects Equipment and Software from Varian Medical Systems for Major Replacement Project
9. Scorpion Offshore Inc. Pilot Project With InPlace Medical Solutions Sets New Standard for Offshore Medical Services
10. Quick Medical Posts Record Sales During Economic Downturn
11. Study finds pay for performance stimulates changes in medical practice
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/27/2016)... ... ... recently awarded their highest five-star rating to Best Buy Eyeglasses, an ... United States and Canada wear eyeglasses. Once considered to be a purely functional part ... fashion statement. Even celebrities use glasses as a way of creating an iconic image—like ...
(Date:6/26/2016)... ... , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center ... Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This annual ... the world’s leading providers of cereal and other breakfast foods. Its residents often refer ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology: